Edition:
India

Eiger BioPharmaceuticals Inc (EIGR.OQ)

EIGR.OQ on NASDAQ Stock Exchange Global Market

11.58USD
20 Sep 2019
Change (% chg)

$-0.03 (-0.26%)
Prev Close
$11.61
Open
$11.60
Day's High
$11.82
Day's Low
$11.53
Volume
104,569
Avg. Vol
76,002
52-wk High
$15.30
52-wk Low
$8.51

Latest Key Developments (Source: Significant Developments)

Eiger BioPharmaceuticals Reports Q2 Loss Per Share $0.75
Friday, 9 Aug 2019 

Aug 8 (Reuters) - Eiger BioPharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q2 LOSS PER SHARE $0.75.Q2 EARNINGS PER SHARE ESTIMATE $-0.74 -- REFINITIV IBES DATA.NDA AND MAA FILINGS FOR PROGERIA & PROGEROID LAMINOPATHIES PLANNED FOR Q4 2019.  Full Article

Eiger Biopharmaceuticals Q1 Loss Per Share $0.90
Friday, 10 May 2019 

May 9 (Reuters) - Eiger BioPharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q1 LOSS PER SHARE $0.90.Q1 EARNINGS PER SHARE ESTIMATE $-0.95 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS AS OF MARCH 31, 2019 TOTALED $85.8 MILLION.  Full Article

Eiger Biopharmaceuticals Q4 Loss Per Share $0.92
Friday, 15 Mar 2019 

Eiger BioPharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q4 LOSS PER SHARE $0.92.AS OF DECEMBER 31, 2018, COMPANY HAD 19.2 MILLION OF COMMON SHARES OUTSTANDING..  Full Article

Eiger's Lonafarnib Gets Breakthrough Therapy Label In Progeria And Progeroid Laminopathies
Wednesday, 19 Dec 2018 

Dec 19 (Reuters) - Eiger BioPharmaceuticals Inc ::EIGER ANNOUNCES BREAKTHROUGH THERAPY DESIGNATION GRANTED BY FDA FOR LONAFARNIB IN PROGERIA AND PROGEROID LAMINOPATHIES.EIGER BIOPHARMACEUTICALS INC - NDA FILING PLANNED IN 2019.  Full Article

Eiger Announces Prime Designation Granted By European Medicines Agency For Lonafarnib For Treatment Of Hepatitis Delta Virus Infection
Tuesday, 18 Dec 2018 

Dec 18 (Reuters) - Eiger BioPharmaceuticals Inc ::EIGER ANNOUNCES PRIME DESIGNATION GRANTED BY EUROPEAN MEDICINES AGENCY FOR LONAFARNIB FOR TREATMENT OF HEPATITIS DELTA VIRUS INFECTION.EIGER BIOPHARMACEUTICALS INC - PHASE 3 HDV "D-LIVR" INTERNATIONAL STUDY INITIATING.  Full Article

Eiger Biopharmaceuticals announces the appointment of Sri Ryali as chief financial officer
Tuesday, 4 Dec 2018 

Dec 3 (Reuters) - Eiger BioPharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS ANNOUNCES THE APPOINTMENT OF SRI RYALI AS CHIEF FINANCIAL OFFICER.EIGER BIOPHARMACEUTICALS INC - JAMES WELCH, EIGER'S PREVIOUS CHIEF FINANCIAL OFFICER, HAS LEFT COMPANY.  Full Article

Eiger Bio Reports Q3 Loss Per Share $1.20
Friday, 9 Nov 2018 

Nov 9 (Reuters) - Eiger BioPharmaceuticals Inc ::EIGER BIO REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $1.20.Q3 EARNINGS PER SHARE VIEW $-0.74 -- THOMSON REUTERS I/B/E/S.HDV PHASE 3 D-LIVR STUDY START IN 2018 AND PROGERIA NDA PLANNED IN 2019.EIGER BIOPHARMACEUTICALS - "COMPANY IS NOW PREPARING NEW DRUG APPLICATION IN PROGERIA, ENROLLING FIRST-EVER PHASE 3 STUDY IN HEPATITIS DELTA VIRUS INFECTION"."TARGETING REGULATORY GUIDANCE IN POST-BARIATRIC HYPOGLYCEMIA (PBH) IN 2019".  Full Article

Eiger Biopharmaceuticals Inc Qtrly Loss Per Share $0.82
Friday, 10 Aug 2018 

Aug 10 (Reuters) - Eiger BioPharmaceuticals Inc ::QTRLY LOSS PER SHARE $0.82.Q2 EARNINGS PER SHARE VIEW $-0.82 -- THOMSON REUTERS I/B/E/S.  Full Article

Eiger Biopharmaceuticals Announces Proposed Public Offering Of Common Stock
Thursday, 24 May 2018 

May 23 (Reuters) - Eiger BioPharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.EIGER BIOPHARMACEUTICALS INC - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF ITS COMMON STOCK.EIGER BIOPHARMACEUTICALS - PLANS TO USE NET PROCEEDS TO FUND PLANNED PHASE 3 CLINICAL TRIAL OF LONAFARNIB IN HEPATITIS DELTA VIRUS INFECTION, OTHERS.  Full Article

Eiger Biopharmaceuticals Reports First Quarter 2018 Financial Results
Friday, 11 May 2018 

Eiger BioPharmaceuticals Inc ::EIGER BIOPHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.84.Q1 EARNINGS PER SHARE VIEW $-1.04 -- THOMSON REUTERS I/B/E/S.AS OF MARCH 31, 2018, EIGER HAD CASH, CASH EQUIVALENTS AND SHORT-TERM DEBT SECURITIES OF $33.2 MILLION.  Full Article